Free Newsletter
Dendreon jumps on 'heavyweight' board appointments
Few vaccine companies get a big bump in their stock prices when they add members to their boards. But you don't often get "heavyweight gunslingers" like these. Dendreon, which is nearing an NDA for Provenge, announced that Genentech CEO Ian Clark and Pedro Granadillo, who had been Eli Lilly's top manufacturing aficionado, are coming on board. And investors bid up their shares by eight percent. Dendreon release | Report
More stories about Dendreon
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
